Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart Inc

News

Health Care

Press Releases

General

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Vicarious Surgical Announces Election of New Directors

OTC Markets Group Welcomes Vaxart, Inc. to OTCQX

Vaxart Announces Trading on OTCQX Best Market

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13

Vaxart CEO Issues Letter to Stockholders

Earnings

Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

Vaxart to Host Virtual Stockholder Fireside Chat on Wednesday, August 20 to Discuss Reverse Stock Split Proposal

Comments

Vaxart

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL